|
|
|
| Research progress on the biological role of CD155 and its application in bladder cancer |
| ZHANG Yawei SHI Hongjin WANG Haifeng |
| Department of Urology, the Second Affiliated Hospital of Kunming Medical University Yunnan Research Institute of Urological Disease, Yunnan Province, Kunming 650101, China |
|
|
|
|
Abstract CD155 is a glycoprotein in the immunoglobulin superfamily, which is involved in cell motility, signaling, and T-cell-mediated immunity. It can mediate oncologic immunity by interacting with ligands（TIGIT, CD96, and CD226） to regulate the function of tumor infiltrating lymphocytes. CD155 is up-regulated in bladder cancer and plays an important regulatory role in the invasion of bladder cancer, which is associated with poor prognosis of patients. Immunotherapy that blocks CD155 signal is expected to improve the prognosis of patients with bladder cancer. In this paper, the biological effects of CD155 and its application in bladder cancer are reviewed from the aspects of immune regulation of CD155, the diagnostic value for bladder cancer, and the relationship with the prognosis of patients with bladder cancer and related immunotherapy, in order to provide new ideas for the diagnosis and treatment of bladder cancer.
|
|
|
|
|
|
[1] Matsuo T，Iguchi-Manaka A，Shibuya A，et al. CD155 mutation （Ala67Thr） increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT [J]. Cancer Sci，2022，113（11）：4001-4004.
[2] Yoshikawa K，Ishida M，Yanai H，et al. Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients [J]. PLoS One，2021，16（6）：e0253176.
[3] Nandi SS，Gohil T，Sawant SA，et al. CD155：A Key Receptor Playing Diversified Roles [J]. Curr Mol Med，2022，22（7）：594-607.
[4] Zhu X，Liang R，Lan T，et al. Tumor-associated macrophage- specific CD155 contributes to M2-phenotype transition，immunosuppression，and tumor progression in colorectal cancer [J]. J Immunother Cancer，2022，10（9）：e004219.
[5] Liu L，Wang Y，Geng C，et al. CD155 Promotes the Progression of Cervical Cancer Cells Through AKT/mTOR and NF-κB Pathways [J]. Front Oncol，2021，11：655302.
[6] Kaito Y，Hirano M，Futami M，et al. CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia [J]. Oncol Lett，2022，23（2）：51.
[7] Religioni U，Czerw A，Deptala A. Assessment of Pain，Acceptance of Illness，Adaptation to Life，and Strategies of Coping With the Disease，in Patients With Bladder Cancer [J]. In Vivo，2021，35（2）：1157-1161.
[8] Wang S，Jin S，Shu Q，et al. Strategies to Get Drugs across Bladder Penetrating Barriers for Improving Bladder Cancer Therapy [J]. Pharmaceutics，2021，13（2）：166.
[9] 李彦泽，王磊，陈志远，等.晚期膀胱癌PD-1/PD-L1抑制剂治疗的研究进展[J].中国医药导报，2020，17（4）：40-43，51.
[10] Li S，McLendon R，Sankey E，et al. CD155 is a putative therapeutic target in medulloblastoma [J]. Clin Transl Oncol，2023，25（3）：696-705.
[11] Kyrysyuk O，Wucherpfennig KW. Designing Cancer Immunotherapies That Engage T Cells and NK Cells [J]. Annu Rev Immunol，2023，41：17-38.
[12] Ku■an Brli■ P，Lenac Rovi■ T，Cinamon G，et al. Targeting PVR （CD155） and its receptors in anti-tumor therapy [J]. Cell Mol Immunol，2019，16（1）：40-52.
[13] Xin H，Liu Y，Chen P，et al. CD155 promotes radioresistance and malignancy of esophageal cancer by regulating Hippo-YAP pathway [J]. Discov Oncol，2022，13（1）：53.
[14] Ohtsuki S，Wang C，Watanabe R，et al. Deficiency of the CD155-CD96 immune checkpoint controls IL-9 production in giant cell arteritis [J]. Cell Rep Med，2023，4（4）：101012.
[15] Harjunp?覿?覿 H，Guillerey C. TIGIT as an emerging immune checkpoint [J]. Clin Exp Immunol，2020，200（2）：108-119.
[16] Li XY，Das I，Lepletier A，et al. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms [J]. J Clin Invest，2022，132（6）：e159825.
[17] Zheng Q，Gao J，Yin P，et al. CD155 contributes to the mesenchymal phenotype of triple-negative breast cancer [J]. Cancer Sci，2020，111（2）：383-394.
[18] Pescia C，Pini G，Olmeda E，et al. TIGIT in Lung Cancer：Potential Theranostic Implications [J]. Life （Basel），2023， 13（4）：1050.
[19] 朱艳君，李晶晶，孙琦，等.TIGIT/CD155在恶性肿瘤中的研究进展[J].临床与实验病理学杂志，2021，37（6）：709-712.
[20] Yue J，Li J，Ma J，et al. Myeloid-derived suppressor cells inhibit natural killer cells in myelodysplastic syndromes through the TIGIT/CD155 pathway [J]. Hematology，2023， 28（1）：2166333.
[21] Liu L，You X，Han S，et al. CD155/TIGIT，a novel immune checkpoint in human cancers （Review） [J]. Oncol Rep，2021， 45（3）：835-845.
[22] Paw?覥owska A，Skiba W，Suszczyk D，et al. The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients [J]. Cancers （Basel），2022，14（23）：5757.
[23] Feng S，Isayev O，Werner J，et al. CD96 as a Potential Immune Regulator in Cancers [J]. Int J Mol Sci，2023，24（2）：1303.
[24] Molfetta R，Zitti B，Lecce M，et al. CD155：A Multi-Functional Molecule in Tumor Progression [J]. Int J Mol Sci，2020， 21（3）：922.
[25] 马莉，刘红刚.脊髓灰质炎病毒受体的生物学特性及其在肿瘤免疫中的研究进展[J].中日友好医院学报，2021， 35（6）： 350-352.
[26] Mori K，Matsumoto K，Amano N，et al. Expression of Membranous CD155 Is Associated with Aggressive Phenotypes and a Poor Prognosis in Patients with Bladder Cancer [J]. Cancers （Basel），2022，14（6）：1576.
[27] 陈晔.协同共抑制分子TIGIT/CD155与PD-1在浸润性膀胱癌中的表达及其临床意义[D].乌鲁木齐：新疆医科大学，2022.
[28] Ma W，Ma J，Lei T，et al. Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody [J]. J Cancer，2019，10（21）：5153-5161.
[29] Luo C，Ye W，Hu J，et al. A Poliovirus Receptor （CD155）- Related Risk Signature Predicts the Prognosis of Bladder Cancer [J]. Front Oncol，2021，11：660273.
[30] Zhang J，Zhu Y，Wang Q，et al. Poliovirus receptor CD155 is up-regulated in muscle-invasive bladder cancer and predicts poor prognosis [J]. Urol Oncol，2020，38（2）：41.e11- 41.e18.
[31] Desjardins A，Gromeier M，Herndon JE， et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus [J]. N Engl J Med，2018，379（2）：150-161.
[32] Zhang H，Yang Z，Du G，et al. CD155-Prognostic and Immunotherapeutic Implications Based on Multiple Analyses of Databases Across 33 Human Cancers [J]. Technol Cancer Res Treat，2021，20：1533033820980088. |
|
|
|
